These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18090678)

  • 1. Cardiovascular disease in dialysis patients: do some antihypertensive drugs have specific antioxidant effects or is it just blood pressure reduction? Does antioxidant treatment reduce the risk for cardiovascular disease?
    Aslam S
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):99-105. PubMed ID: 18090678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of microalbuminuria in achieving blood pressure goals.
    Duka I; Bakris G
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):457-63. PubMed ID: 18695385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review.
    Johnson DW; Craven AM; Isbel NM
    Hemodial Int; 2007 Jan; 11(1):1-14. PubMed ID: 17257349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant therapy in uremia: evidence-based medicine?
    Gordon CA; Himmelfarb J
    Semin Dial; 2004; 17(5):327-32. PubMed ID: 15461735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New onset diabetes during antihypertensive therapy.
    Alderman MH
    Am J Hypertens; 2008 May; 21(5):493-9. PubMed ID: 18437139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does dosing antihypertensive drugs at night alter renal or cardiovascular outcome: do we have the evidence?
    Stergiou GS; Nasothimiou EG
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):464-9. PubMed ID: 18695386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren: renin inhibitor for hypertension management.
    Cheng JW
    Clin Ther; 2008 Jan; 30(1):31-47. PubMed ID: 18343241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient.
    Agarwal R
    Curr Opin Nephrol Hypertens; 2007 Sep; 16(5):409-15. PubMed ID: 17693754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of home intensive hemodialysis.
    Chan CT
    Adv Chronic Kidney Dis; 2009 May; 16(3):173-8. PubMed ID: 19393967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension is harmful to dialysis patients and should be controlled.
    Foley RN; Agarwal R
    Semin Dial; 2007; 20(6):518-22. PubMed ID: 17991197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents?
    Armario P; de la Sierra A
    Ther Adv Cardiovasc Dis; 2009 Jun; 3(3):197-204. PubMed ID: 19443514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.